|
Oct 9
|
Aethlon Medical Inc (AEMD) Q1 2025 Earnings Call Highlights: Strategic Cost Management and ...
|
|
Oct 8
|
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Sep 20
|
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
|
|
Sep 19
|
Immunotherapy Clinical Trials - A New Approach to Treating Cancer
|
|
Sep 19
|
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
|
|
Sep 17
|
Aethlon Medical to Present at Virtual Investor Conferences in September
|
|
Sep 17
|
Innovation Driving Cancer's Solid Tumors Market
|
|
Sep 16
|
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
|
Sep 16
|
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
|
|
Aug 27
|
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
|
|
Jul 8
|
AEMD: Approval from 1st Site, Submitting to Additional Sites for Oncology Trial
|
|
Jun 27
|
Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update
|
|
Jun 24
|
AEMD: Ethics Committee Approval for Safety, Feasibility, Dose-Finding Trial Important Step in Advancing the Hemopurifier
|
|
Jun 21
|
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
|
|
Jun 7
|
The Hunt for Virus Treatments Continues Post Covid-19
|
|
Jun 3
|
Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID
|
|
Jun 3
|
Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
|
|
May 15
|
Aethlon Medical Announces Pricing of $4.7 Million Public Offering
|
|
May 13
|
AEMD: Data From In Vitro Study Supports Advancing Planned Oncology Clinical Trial
|
|
May 10
|
Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
|